Gene therapy has a $1M+ delivery problem. ViaNautis is solving it with polyNaut® nanovesicles—modular, non-viral delivery systems that promise to make cell and gene therapies safer, cheaper, and more precise. This isn't incremental innovation; it's a platform shift.

"ViaNautis isn't just building a biotech company—they're building the infrastructure for the next decade of genetic medicine."

The biotech industry is at an inflection point. Cell and gene therapies are generating unprecedented clinical results, but delivery remains the Achilles' heel. Viral vectors—while effective—come with immunogenicity risks, manufacturing complexity, and limited cargo capacity. ViaNautis's approach addresses all three simultaneously.

• Platform technology with modular design for multiple therapeutic applications
• Non-viral delivery eliminates immune response risks and manufacturing bottlenecks
• Targeted delivery to specific cell types increases efficacy while reducing systemic toxicity
• Scalable manufacturing could dramatically lower costs compared to viral vectors